External radiation exposure, excretion, and effective half-life in (177)Lu-PSMA-targeted therapies

BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with (177)Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurth, J., Krause, B. J., Schwarzenböck, S. M., Stegger, L., Schäfers, M., Rahbar, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897276/
https://www.ncbi.nlm.nih.gov/pubmed/29651569
http://dx.doi.org/10.1186/s13550-018-0386-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897276/
https://www.ncbi.nlm.nih.gov/pubmed/29651569
http://dx.doi.org/10.1186/s13550-018-0386-4

Ejemplares similares